

NCIC CLINICAL TRIALS GROUP

**GASTROINTESTINAL**

DISEASE SITE COMMITTEE MEETING

AGENDA

**OPEN (& CLOSED\*) SESSIONS**

Venue: Delta Chelsea Hotel

Date: Sunday, May 4<sup>th</sup>, 2008

Time: 8:30 am – 3:30 pm

Chair: Dr. Derek Jonker

Room: Churchill Ballroom A

---

|         |   |                  |
|---------|---|------------------|
| 8:30 am | <b>WELCOME AND INTRODUCTION</b>   | Dr. D. Jonker    |
| 8:40 am | <b>RECENTLY ACTIVATED TRIALS</b>  |                  |
|         | <b>BI.1:</b> A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) versus Gemcitabine Alone in Advanced Biliary Cancer  | Dr. J. Knox      |
|         | <b>CO.20:</b> A Phase III Randomizes Study of Brivanib Alaninate (BMS-582664) in Combination With Cetuximab (Erbix <sup>®</sup> ) versus Placebo in Combination with Cetuximab (Erbix <sup>®</sup> ) in Patients Previously Treated with Combination Chemotherapy for Metastatic Colorectal Carcinoma | Dr. L. Siu       |
|         | <b>CRC.5</b> (CALGB 80405): A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5FU / Leucovorin with Bevacizumab, or Cetuximab, or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum                   | Dr. S. Berry     |
| 9:25 am | <b>ACTIVE TRIALS</b>  |                  |
|         | <b>ES.2</b> (TROG 03.01): A Randomised Phase III Study in Advanced Oesophageal Cancer to Compare Quality of Life and palliation of Dysphagia in Patients Treated with Radiotherapy versus Chemo-Radiotherapy  | Dr. M. Penniment |
|         | <b>GAC.1</b> (CALGB-80101): A Phase III Trial of Adjuvant Chemoradiation After Resection of GastricOr Gastroesophageal Adenocarcinoma   | Dr. G. Bjarnason |
|         | <b>CRC.2</b> (NCCTG N0147): A Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer   | Dr. S. Gill      |
|         | <b>CRC.3</b> (ECOG E5202): A Randomized Phase III Study Comparing 5-FU Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers.       | Dr. C. Butts     |
|         | <b>CRC.4</b> (ECOG E5204): Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation.                       | Dr. J. Brierley  |
|         | <b>PA.2</b> (ESPAC-3): Adjuvant Chemotherapies in Resectable Pancreatic Cancer  | Dr. M. Moore     |

**IND.171:** Phase I Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination with Standard Chemotherapy in Patients with Advanced Incurable NSCLC or CRC Dr. D. Jonker

**IND.187:** A Phase I Study Of AZD2281 In Combination With Irinotecan In Patients With Locally Advanced or Metastatic Incurable Colorectal Cancer Dr. E. Chen

10:20 am **APPROVED TRIALS IN DEVELOPMENT**

**CO.21:** A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients with Early Stage Colon Cancer: A Randomized Controlled Trial (CHALLENGE) Dr. C. Booth

10:30 am **IND REPORT** Dr. M. Moore

10:40 am **REFRESHMENT BREAK**

11:00 am

**SESSION CLOSED TO NCIC CTG MEMBERS AND INVITED GUESTS**

**CO.17:** A Phase III Randomized Study of Cetuximab (Erbix<sup>TM</sup>, C225) and Best Supportive Care versus Best Supportive Care in Patients with Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma

K-Ras Correlative Analyses Results Dr. C. Karapetis

Discussion Dr. D. Jonker

12:00 pm **LUNCH**

1:00 pm **DISEASE ORIENTED WORKING GROUP REPORTS / NEW TRIAL PROPOSALS**

**Colon DOG** Dr. D. Jonker / Dr. S. Gill

**Rectal DOG** Dr. N. Baxter

**Esophageal / Gastric DOG** Dr. Rebecca Wong / Dr. C. Kollmannsberger

**Pancreas DOG** Dr. M. Moore / Dr. S. Gallinger

**Hepatobiliary DOG** Dr. O. Bathe / Dr. J. Knox

**Neuroendocrine DOG** Dr. Lillian Siu / Dr. W. Kocha

3:00 pm **GI INTERGROUP UPDATE** Dr. D. Jonker

3:15 pm **CLOSING REMARKS & ADJOURNMENT** Dr. D. Jonker

3:30 pm **CLOSED SESSION: GI EXECUTIVE MEETING** Dr. D. Jonker